Another retrospective study from the MD Anderson Cancer Center showed a prolonged OS in TP53-mutated AML treated with allogeneic HSCT compared with TP53-mutated AML not treated with allogeneic HSCT (median OS 33.7 months vs. 7.0 months), but the Kaplan–Meyer graph in this article strongly suggested that even allogeneic HSCT is not curative for TP53-mutated AML [97]. This evidence concerns the gene TP53 and acute myeloid leukemia.